# Candesartan

Drug · id `cardio:candesartan` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Atacand; Candesartan cilexetil

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: High blood pressure; Heart failure  

## In plain language

Candesartan is an ARB (angiotensin II receptor blocker), a medicine taken by mouth. The US label read, for ATACAND tablets (candesartan cilexetil), lists two uses: treating high blood pressure in adults and in children 1 to under 17 years of age, and treating heart failure (NYHA class II-IV), where the label says it reduces cardiovascular death and heart failure hospitalization. Atacand is the brand name on the label read.

## Technical summary

RxNorm ingredient 214354; UNII R85M2X0D68. The label names the substance as candesartan cilexetil, a prodrug that the label says is hydrolyzed to candesartan, so UNII R85M2X0D68 is the UNII of the cilexetil ester and is a broad match. MeSH has no descriptor for candesartan; C077793 is the MeSH supplementary concept record for candesartan cilexetil, also a broad match. Class: Angiotensin 2 Receptor Blocker (FDA established pharmacologic class, RxClass). The label read is the ANI Pharmaceuticals, Inc. label for ATACAND (candesartan cilexetil) tablets, application NDA020838, effective 2025-12-22 in openFDA; Drugs@FDA lists the application's sponsor as ANI PHARMS. Generic candesartan labels and the ATACAND HCT combination label were not read. This page records label indications and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Patients for whom the US label of candesartan (Atacand) lists an indication: adult hypertension, NYHA class II-IV heart failure

Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The hypertension indication names adults (and, separately, children 1 to under 17 years of age); the heart failure indication does not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults for hypertension, as the passage read states; not stated for heart failure; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of ATACAND (candesartan cilexetil) tablets, in the ANI Pharmaceuticals, Inc. version dated 2025-12-22 in openFDA, lists the medicine for the treatment of hypertension in adults, to lower blood pressure (the same label sentence also names children 1 to under 17 years of age, recorded separately); and for the treatment of heart failure (NYHA class II-IV), with the label stating that the medicine reduces cardiovascular death and heart failure hospitalization.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The hypertension indication names adults (and, separately, children 1 to under 17 years of age); the heart failure indication does not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults for hypertension, as the passage read states; not stated for heart failure; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for ATACAND (candesartan cilexetil) tablets, ANI Pharmaceuticals, Inc. label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 94a59260-d2b6-464a-b5b9-bbc599e57e10 (manufacturer ANI Pharmaceuticals, Inc., application NDA020838), returned on 2026-11-09. The label text is dated 2025-12-22 (effective\_time). Other openFDA records of candesartan labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2294a59260-d2b6-464a-b5b9-bbc599e57e10%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-09T13:19:06Z. Source state: Current. Version fingerprint: 6e366d099c851afcac0f711669c077763a34505dc03331674c97f4d2f3593f5a.
     How it applies: The label sentences that give the indications named in the statement, each quoted in the research quote table.
  2. Background: openFDA drug label record for ATACAND (candesartan cilexetil) tablets, ANI Pharmaceuticals, Inc. label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 94a59260-d2b6-464a-b5b9-bbc599e57e10 (manufacturer ANI Pharmaceuticals, Inc., application NDA020838), returned on 2026-11-09. The label text is dated 2025-12-22 (effective\_time). Other openFDA records of candesartan labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2294a59260-d2b6-464a-b5b9-bbc599e57e10%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:19:06Z. Source state: Current. Version fingerprint: 6e366d099c851afcac0f711669c077763a34505dc03331674c97f4d2f3593f5a.
     How it applies: Effective date of the label text read, 20251222.
  3. Background: openFDA Drugs@FDA record for application NDA020838 (ATACAND, sponsor ANI PHARMS): product and sponsor (Regulator, edition The openFDA Drugs@FDA record for application NDA020838, returned on 2026-11-09. It lists the sponsor and the products of the application; only the first product listing is quoted.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA020838%22&limit=1>
     Locator: results\[0\].products\[0\].brand\_name. Retrieved 2026-11-09T13:20:36Z. Source state: Current. Version fingerprint: ec1683f25cf3821591331aea65021120395a52d28829ac5fc903c50d651cbef8.
     How it applies: Drugs@FDA product listing for application NDA020838, which confirms the product the label belongs to.

## Context: Children for whom the US label of candesartan (Atacand) lists hypertension as an indication: children 1 to under 17 years of age

Recipient: Child; Population: Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Label wording: children 1 to under 17 years of age; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of ATACAND (candesartan cilexetil) tablets, in the ANI Pharmaceuticals, Inc. version dated 2025-12-22 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure, in children 1 to under 17 years of age.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Child; Population: Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Label wording: children 1 to under 17 years of age; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for ATACAND (candesartan cilexetil) tablets, ANI Pharmaceuticals, Inc. label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 94a59260-d2b6-464a-b5b9-bbc599e57e10 (manufacturer ANI Pharmaceuticals, Inc., application NDA020838), returned on 2026-11-09. The label text is dated 2025-12-22 (effective\_time). Other openFDA records of candesartan labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2294a59260-d2b6-464a-b5b9-bbc599e57e10%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-09T13:19:06Z. Source state: Current. Version fingerprint: 6e366d099c851afcac0f711669c077763a34505dc03331674c97f4d2f3593f5a.
     How it applies: The label sentence that names children in the hypertension indication, quoted in the research quote table.
  2. Background: openFDA drug label record for ATACAND (candesartan cilexetil) tablets, ANI Pharmaceuticals, Inc. label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 94a59260-d2b6-464a-b5b9-bbc599e57e10 (manufacturer ANI Pharmaceuticals, Inc., application NDA020838), returned on 2026-11-09. The label text is dated 2025-12-22 (effective\_time). Other openFDA records of candesartan labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2294a59260-d2b6-464a-b5b9-bbc599e57e10%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:19:06Z. Source state: Current. Version fingerprint: 6e366d099c851afcac0f711669c077763a34505dc03331674c97f4d2f3593f5a.
     How it applies: Effective date of the label text read, 20251222.

## Connected pages

- Candesartan is an ARB (FDA established pharmacologic class in RxClass): Angiotensin receptor blockers (ARBs) (`cardio:angiotensin-receptor-blockers-arbs`)
- FDA label lists hypertension as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-candesartan-label-indications` and its context]
- FDA label lists NYHA class II to IV heart failure as an indication: Heart failure (`cardio:heart-failure`) [a claim, not a settled fact; see claim `cardio:claim-fda-candesartan-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 2 registry products
- 8 registry trials

## Provenance

Content hash: 2731a12b2f9c4c04b600b2872d010a8589c82f9aeffb9935a0b52ba638fba0a2
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
